Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nalbuphine is a semi-synthetic opioid analgesic classified as a mixed agonist-antagonist. It primarily acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors. This dual mechanism provides effective analgesia comparable to morphine but with a lower risk of respiratory depression and dependence. Nalbuphine is used for the management of moderate to severe pain, including postoperative pain, cancer pain, and pain associated with various medical conditions. Its onset of action is rapid (5–10 minutes), with effects lasting 3–6 hours. Compared to traditional opioids like morphine or fentanyl, nalbuphine has fewer side effects such as pruritus (itching), nausea, vomiting, and less potential for abuse or addiction[1][4][5][6]. It can be used alone or in combination with other analgesics in multimodal pain management strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nalbuphine.